Selected disease-modifying antirheumatic drugs
| Antimetabolite |
| Methotrexate |
| Tumor necrosis factor inhibitors |
| Adalimumab |
| Certolizumab |
| Etanercept |
| Golimumab |
| Infliximab |
| Anti-CD80/CD86 |
| Abatacept |
| Janus kinase inhibitors |
| Baricitinib |
| Tofacitinib |
| Upadacitinib |
| Anti-CD20 |
| Rituximab |
| Interleukin (IL-) 6 inhibitors |
| Sarilumab |
| Siltuximab |
| Tocilizumab |
| IL-17 inhibitors |
| Brodalumab |
| Ixekizumab |
| Secukinumab |
| IL-12/23 inhibitors |
| Ustekinumab |